Aclaris Therapeutics, Inc. (ACRS) Stock Grade

About Aclaris Therapeutics, Inc.'s fundamentals

Aclaris Therapeutics is a biotechnology company with a market capitalization of $758.4 million that is currently unprofitable, reporting a net margin of -829.6% and a significant net loss in its latest annual statement. The company experienced a steep revenue decline of 58.2% year-over-year, indicating a substantial contraction in its business. With no dividend yield and traditional valuation metrics unavailable due to its loss-making status, the company is in a development or turnaround phase typical of early-stage biotech firms.